Trinity College Dublin

Skip to main content.

Top Level TCD Links

Image of exterior
Image of Boardroom
Discover Research Dublin
Image of anatomy

Latest Discoveries & Publications

Gavin Davey New Language for Cells: Ground-breaking study that merges linguistics, biochemistry, computer science and mathematics. Scientists, led by TBSI's Professor Gavin Davey, (with awards for funding for the interdisciplinary study provided by EU Marie Curie and Science Foundation Ireland) have written a formal language that enables deciphering of the highly complex manner in which proteins are modified by sugar molecules read more

Immunology Discovery by immunologists at TBSI has just been published in the journal Immunity. Professor in Immunology Ed Lavelle, from Trinity’s School of Biochemistry &Immunology and AMBER - the Science Foundation Ireland funded materials science centre - and Dr Elizabeth Carroll have uncovered the mechanism by which a promising vaccine adjuvant, chitosan, induces an immune response. The Trinity team’s discovery provides a roadmap to develop vaccines that trigger ‘cell-mediated immunity’. Read Trinity Communications Office's article Immunity Journal pdf 3.19mb

Science Congratulations to Ed Lavelle, Cliona Ni Cheallaigh and other members of the Lavelle and O¹Neill groups in TBSI on their recent paper in Immunity. "A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling". paper - (2.93 mb PDF)

Globomycin blocks lipoprotein maturation enzyme LspA
Congratulations to the Membrane Structural & Functional Biology Group on the publication of their Paper in Science. "Structural basis of lipoprotein signal peptidase II action and inhibition by the antibiotic globomycin” Science. 19th February 2016

With antimicrobial resistance on the rise, the World Health Organization has advised that a post-antibiotic era, in which minor injuries and common infections can prove fatal, is looming. New drugs are needed. Globomycin attracted attention as an antibacterial candidate because of the novel peptidase, LspA, it inhibits and the many lipoproteins with critical roles in bacterial physiology, pathogenicity and antibiotic resistance that go unprocessed as a result. The high-resolution structure of LspA inhibited by globomycin reported here can now be used for the design of better globomycin analogues, to explore the thousands of inhibitors developed for other peptidases, and to design entirely new and more effective antibiotics.

Diacylglycerol Congratulations to the Membrane Structural & Functional Biology Group on the publication of their article in Nature Communications "Ternary structure reveals mechanism of a membrane diacylglycerol kinase” Nature Communications. 17th December 2015. Diacylglycerol kinase is a small, integral membrane enzyme that catalyses a complex reaction involving substrates with widely contrasting solubilities. Its lipid substrate is hydrophobic and resides in the membrane while its co-substrate, ATP, is entirely water soluble. How this diminutive nanomachine, less than 10 nanometers tall, brings these two disparate substrates together at the membrane interface for reaction is revealed here in a molecularly detailed crystal structure. As the smallest known kinase, most of its bulk is devoted to creating substrate binding sites. This new structure, solved with the aid of free-electron laser X-rays, contributes to explaining 50 years of work on a paradigmatic enzyme. (PDF 4.21 MB)

Ken Mok Non-Disease Proteins Kill Brain Cells. Congratulations to TBSI's Ken Mok (Associate Professor in Biochemistry) and Gavin Davey (Associate Professor in Neuroscience) who along with several young researchers including Níal Harte and Igor Klyubin, collaborated with Professor of Neuropharmacology, Michael J Rowan, Professor in Chemistry, Principal Investigator in CRANN and Dean of Research, John Boland to complete the research . Dr Kenneth Hun Mok (pictured here) led the study that was published in the Journal of Biological Chemistry (pdf) on Friday 20 November 2015.

Discoveries prior to those listed above

News & Events

Luke O'Neill TBSI'S Luke O’Neill, is one of five academics worldwide to join a new immunology research collaboration programme operated by the global healthcare company, GSK. The Immunology Network hosts global experts to set up research labs called ‘the Immunology Catalyst’. Details here

Luke O'Neill Congratulations to Professor Luke O’Neill who has been elected as a Fellow of the Royal Society, where scientists are elected to the Fellowship by their peers as recognised leaders who have advanced their fields through their ground breaking work. Prof O’Neill has made many contributions to improved knowledge of how the human body works including metabolism, the immune system and cell signalling. He is Professor of Biochemistry in the School of Biochemistry and Immunology in Trinity College Dublin and is a leading researcher in the school and in the Trinity Biomedical Sciences Institute (TBSI), where he was the first Academic Director.

Padraic Fallon In TBSI on 13th April, Minister English announced the recipients of the 2016 SFI-Pfizer Biotherapeutics Innovation Award programme. The collaboration between SFI and Pfizer provides qualified academic researchers with an opportunity to deliver important potential discoveries in the areas of immunology, oncology, cardiovascular and rare diseases. TBSI's Padraic Fallon, one of the 2015 grant recipients, spoke at the event of the positive experiences he and his team have had during the project to date, which have been not only at the research level but also the cultural level, where his research group have adopted organisational practices used by Pfizer. Professor Fallon said that the latter has been an unexpected and welcome benefit from the collaboration.

Luke O'Neill Congratulations to Luke O'Neill who has secured a €2 million Investigator Award announced through the SFI-HRB-Wellcome Trust partnership to investigate totally new theories about how certain cells behave and cause inflammation in the hope of finding new therapies. HRB news

Kingston Mills Congratulations to TBSI's Kingston Mills and Luke O'Neill who have been awarded €2.5million to work on biomarkers and drug targets for autoimmune and other immune-mediated diseases. Professor Mills (pictured) will lead the project. This funding has been provided by SFI and international biopharmaceutical company, AbbVie.

News and Events prior to those listed above

Last updated 6 May 2016 by Caroline Levis (Email).